"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Neotrace®-4 is indicated for use as a supplement to intravenous solution given for TPN. Administration of Neotrace®-4 in TPN solutions helps to maintain plasma levels of zinc, copper, manganese and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms.
DOSAGE AND ADMINISTRATION
The suggested dosage ranges for the four trace elements in neonates and pediatric patients are:
Zinc: For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day is recommended. For premature infants up to 3 kg in body weight, 300 mcg zinc/kg/day is suggested.
Copper: For pediatric patients, the suggested additive dosage level is 20 mcg copper/kg/day.
Manganese: For pediatric patients, a dosage of 2 to 10 mcg manganese/kg/day is suggested.
Chromium: For pediatric patients, the suggested additive dosage is 0.14 to 0.20 mcg/kg/day.
Periodic monitoring of plasma levels of zinc, copper, manganese and chromium is suggested as a guideline preparation.
Aseptic addition of Neotrace®-4 to the TPN solution under a laminar wflow hood is recommended. The trace elements present in Neotrace®-4 are physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN.
Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.
|Neotrace®-4 in a 2 mL single-dose, flip-top vial in trays of 25.|
Preservative Free. Discard unused portion.
Store at controlled room temperature 15°-30° C (59°-86°F).
CAUTION: Federal law prohibits dispensing without prescription.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Neotrace-4 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.